Each year approximately 70,000 patients in the United States are diagnosed with CUP. A patient typically is diagnosed with CUP only after undergoing a wide range of tests, including various imaging tests such as x-ray, CT, MRI, and PET, which have failed to identify the origin of the cancer. Accurately identifying the origin of a metastasis can be critical in guiding treatment decisions.
The study results published in Nature Biotechnology describe the development and test validation of microRNA expression profiles for identification of tumor origin. Rosetta Genomics' scientists measured microRNA expression in RNA extracted from hundreds of formalin-fixed, paraffin-embedded (FFPE) samples from more than 20 different known primary tumor tissues and metastases. These results were used to build a classifier which assigns a primary site to a cancer sample based on the microRNA expression in the sample. The paper demonstrates, based on a blinded test set, that the overall sensitivity of this classifier is approximately 85%, with two-thirds of the samples being classified with high-confidence, reaching accuracy exceeding 90% and specificity of 99%.
"The recognition of our research work by a leading, peer-reviewed journal like Nature Biotechnology is truly exciting," noted Dr. Dalia Cohen, Chief Scientific Officer of Rosetta Genomics. "As a leader in the microRNA field, Rosetta Genomics continues to advance and develop microRNA-based technologies that can potentially be applied in a wide range of diagnostics and therapeutics."
The paper, "MicroRNAs accurately identify cancer tissue origin" will be available on Nature Biotechnology's website on Sunday, March 23rd, and will also appear in the April 2008 Volume 26 No 4 edition of the publication.
MicroRNAs (miRNAs) are recently discovered, naturally occu
|SOURCE Rosetta Genomics Ltd|
Copyright©2008 PR Newswire.
All rights reserved